Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cisco Systems

Intel

With the Dow Jones Industrial Average down 2% so far over the week of May 20, all of the Dow 30 stocks have taken a dip. For the average layman, this means the broader stock market contracted this week, but most professional investors would defer to the S&P 500 which is down an average of 0.74% in the same timeframe.

3 Dow Stocks to Buy on the Dip: May 2024

Amcor Plc

Brookfield Asset Management

Brookfield Renewable Partners

Blackstone Secured Lending Fund

Chevron

Con Ed

Enterprise Products Partners

Federal Realty Investment Trust

Coca-Cola

NextEra Energy

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

W. P. Carey

Dividend Aristocrats are generally excellent stocks for a retiree's passive income portfolio. They generally have wide moats, strong balance sheets, excellent management teams, and the ability to navigate all sorts of economic environments. We provide a diversified portfolio of 10 Dividend Aristocrats that have the potential to fund living expenses indefinitely and grow at a rate that beats inflation.

If I Had To Retire With 10 Dividend Aristocrats, It Would Be These

McDonald's

Restaurant Brands

In today's uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty.

3 Stocks to Safeguard Your Investments During a Market Meltdown

A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.

Cancer victims file class action against Johnson & Johnson over ‘fraudulent' bankruptcies

The Health Care sector has been stagnant while other areas of the stock market reach record highs, leaving some value opportunities in drugmakers and pharma stocks. I have a buy rating on Johnson & Johnson (JNJ) given its stable earnings growth and lofty yield. JNJ's diversified portfolio and pipeline provide stability, despite some weaknesses in certain areas.

Johnson & Johnson: Vital Signs Decent, A Compelling Value Case

A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.

Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies

TRENTON, N.J.--(BUSINESS WIRE)--Women who previously filed lawsuits against Johnson & Johnson for damages caused by its defective talc products have filed a class action lawsuit in U.S. District Court in New Jersey accusing J&J of engaging in a series of fraudulent maneuvers designed to prevent cancer victims and their families from receiving fair compensation for their health-related claims. The lawsuit alleges three specific mileposts in Johnson & Johnson's fraudulent strategy: Th.

Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation

Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.

7 Safe-Haven Stocks to Weather Any Storm

Archer-Daniels-Midland Company

Fortis

Genuine Parts

Lowe's

Procter & Gamble

Fundamentally, the case for dividend kings to buy couldn't be simpler: investors are banking on the proven stability of the underlying enterprises. Since qualifying for the dividend king title involves providing rising annual payouts for at least 50 consecutive years, you can bet that these companies benefit from reliable businesses.

7 Dividend Kings to Buy for Royal Passive Income: May Edition

Johnson & Johnson's dividend currently yields more than 3%. The healthcare giant has increased its payout every year for more than half a century.

Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson Stock

Deere & Company

Intuit

Kroger

Palo Alto Networks

Walmart

Artificial intelligence has taken over business headlines for good reason. Yet, investors may be better served, at this juncture, focusing on underappreciated AI stocks.

The AI Stock Underdogs: 7 Underappreciated Companies Poised for Greatness

Ares Commercial Real Estate

AGNC Investment

Apollo Commercial Real Estate Finance

FS KKR Capital Corp

Medifast

Orchid Island Capital

Oxford Lane Capital

PIMCO Dynamic Income Fund

Ready Capital Corp

V.F.

Prior to April 30, 2024, my Readers mentioned 31 equities in their comments on my articles. Some bad-news investments (Rogues) mixed with (mostly) Favorites. Thus, they remarked about the ReFa/Ro. Ten analyst-target-estimated top net gain ReFa/Ro: ORC, JNJ, CVX, FTN.CA, OXLC, ACRE, MED, RC, INTC, and VFC averaged 22.94% net gains from reader data collected 5/15/23. Ten analyst-target-augured April top price upside reader faves & rogues (ReFa/Ro) were: ORI, O, KVUE, PFE, WES, CVX, JNJ, RC, INTC & VFC boasting a 16.43% average target price upside estimate.

Readers Identify 23 Ideal April Dividend Buys

Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.

J&J-backed startup Rapport files for US IPO

Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.

J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

AbbVie

Boeing

CVS Health

Lockheed Martin

Pfizer

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

7 Value Stocks to Buy and Hold for a Decade of Dominance

Centene

Tenet Healthcare

With the market rally broadening out, value sectors are beginning to catch a bid. Healthcare deserves consideration as one of the value sectors presenting some bargains in this overheating market.

3 Cheap Healthcare Stocks to Buy Now: May 2024

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

News for Johnson & Johnson Stock (JNJ)